News

€10m for crop research
Enlarge image

FundingFranceGermanyPortugalSpain

€10m for crop research

31.07.2012 - The transnational plant genome research funding initiative PLANT-KBBE has published its 6th call: €10m will be provided for crop breeding projects.

The acronym PLANT-KBBE stands for: 'Transnational PLant Alliance for Novel Technologies – towards implementing the Knowledge-Based Bio-Economy in Europe' (PLANT-KBBE) and represents an international funding initiative between France, Spain, Germany and Portugal. National funding partners are the Ministry of Research and Innovation (DGRI) in France, represented by the national funding agency ANR (Agence Nationale de la Recherche), the Ministry of Economy and Competitiveness (MINECO) in Spain, the Federal Ministry of Education and Research (BMBF) in Germany and the Portuguese national funding agency FCT (Fundação para a Ciênca e a Tecnologia). 

Purpose of the call, which is the 6th transnational ‘Call for Proposals’ (‘Food & Feed: crop yields and nutrition security in the context of climate change‘) is the accelerated implementation of practical applications based on achieved scientific findings, accompanied with an immediate transfer of research results in new processes, products and services. The programme targets projects  that are based on the following general research themes: Yield stability, plant health, adaptation to pressures from the environment and phenotypic plasticity. 

The higher purpose of the PLANT-KBBE funding initiative is the implementation, as well as continuation, of transnational research projects between research groups and enterprises of the partner countries mentioned above, with the objective of further deepening the already existing cooperation between economy and science in and between these countries. In the framework of PLANT-KBBE, SMEs are  particularly addressed. The funding partners also intend to support such multi-disciplinary R&D-activities in the context of public-private-partnerships, integrating other research fields apart from plant biotechnology. Full proposals are to be submitted by October 15.

http://www.european-biotechnology-news.com/news/news/2012-03/eur10m-for-transnational-crop-research.html

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MOLOGEN7.65 EUR18.42%
  • BB BIOTECH150.50 EUR5.10%
  • CO.DON2.69 EUR4.26%

FLOP

  • 4SC0.80 EUR-8.05%
  • CYTOS0.16 CHF-5.88%
  • WILEX2.15 EUR-4.44%

TOP

  • BIOFRONTERA2.85 EUR27.2%
  • MOLOGEN7.65 EUR3.4%
  • HBM85.50 CHF3.1%

FLOP

  • PAION2.20 EUR-32.3%
  • 4SC0.80 EUR-29.8%
  • CYTOS0.16 CHF-23.8%

TOP

  • SANTHERA81.90 CHF2267.1%
  • CO.DON2.69 EUR195.6%
  • PAION2.20 EUR155.8%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.80 EUR-54.0%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014